CD19 and acute lymphoblastic leukemia: A study analyzing immunophenotypic changes in leukemic cells at relapse in 90 pediatric R/R ALL patients treated with blinatumomab showed that in 21 cases, leukemia cells at relapse were CD19 positive, whereas in six cases, they were CD19 negative [43].